Eltanexor Effectively Reduces Viability of Glioblastoma and Glioblastoma Stem-Like Cells at Nano-Molar Concentrations and Sensitizes to Radiotherapy and Temozolomide

Current standard adjuvant therapy of glioblastoma multiforme (GBM) using temozolomide (TMZ) frequently fails due to therapy resistance. Thus, novel therapeutic approaches are highly demanded. We tested the therapeutic efficacy of the second-generation XPO1 inhibitor Eltanexor using assays for cell v...

Descripción completa

Detalles Bibliográficos
Autores principales: Otte, Katharina, Zhao, Kai, Braun, Madita, Neubauer, Andreas, Raifer, Hartmann, Helmprobst, Frederik, Barrera, Felipe Ovalle, Nimsky, Christopher, Bartsch, Jörg W., Rusch, Tillmann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496210/
https://www.ncbi.nlm.nih.gov/pubmed/36140245
http://dx.doi.org/10.3390/biomedicines10092145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496210/
https://www.ncbi.nlm.nih.gov/pubmed/36140245
http://dx.doi.org/10.3390/biomedicines10092145

Ejemplares similares